/
ERNA
$7.03+$0.06 (+0.86%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$8.1M
1M shares
52-week range
$3.18 – $71.50
6% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
311.22%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1837.97
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.3M | $19.8M | $0 | $0 | $0 | $68.0K | $582.0K | $0 |
| Cost of revenue | $8.4M | $7.8M | $98.0K | $0 | $0 | $236.0K | $96.0K | $0 |
| Gross profit | $14.9M | $12.0M | −$98.0K | $0 | $0 | −$168.0K | $486.0K | $0 |
| Gross margin | 64.1% | 60.4% | — | — | — | -247.1% | 83.5% | — |
| R&D | $72.0K | $26.0K | $4.0M | $12.7M | $10.4M | $5.9M | $4.6M | $4.2M |
| Operating income | $464.0K | −$1.2M | −$7.2M | −$113.7M | −$33.2M | −$21.1M | −$15.7M | −$9.3M |
| EBITDA | $3.2M | $1.4M | −$26.4M | −$121.9M | −$24.0M | −$19.9M | −$36.1M | −$13.8M |
| Net income | −$259.0K | −$2.0M | $11.9M | −$122.5M | −$24.6M | −$21.7M | −$44.5M | −$14.1M |
| Net margin | -1.1% | -10.3% | — | — | — | -31864.7% | -7652.7% | — |
| EPS (diluted) | -96.25 | -712.00 | -87.75 | -1415.25 | -201.50 | -102.00 | -39.25 | -56.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $75M | $-18.02 | $-18.02–$-18.02 | 1 |
| 2027 | $0 | $-1.86 | $-1.86–$-1.86 | 1 |
| 2028 | $0 | $-1.27 | $-1.27–$-1.27 | 1 |
| 2029 | $0 | $-1.44 | $-1.44–$-1.44 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.93
Price
$7.03
Implied downside
-73%
Peer comparison
Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
www.ernexatx.com- Employees
- 5
- IPO / List date
- Mar 26, 2021
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds ERNA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ERNA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-05-04 | 1-for-25reverse |
| 2025-06-12 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded ERNA yet.
